Jazz Pharmaceuticals plc

JAZZ

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001193210-26-000005
Filing date: Mar 4, 2026
Earliest execution date: Mar 3, 2026
Reporting Owners: COZADD BRUCE C (Director)

Summary

Type

Sell

Net shares

-6,000

% of shares

-1.46%

Amount (USD)

$1,118,613

Insider confidence score

43.8 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Moderate scheduled sell (<2% of shares)
  • Very large sell amount ($1M+)

Stock transactions

Transaction 1

Security

Ordinary Shares

Action

Sell

Date

2026-03-03

Code

S

Net shares

-3,159.0

Price per Share

$186.09

Amount (USD)

$587,843.46

Acquired/Disposed

Disposed

Shares Owned Before

411,796.0

Shares Owned After

408,637.0

Transaction 2

Security

Ordinary Shares

Action

Sell

Date

2026-03-03

Code

S

Net shares

-2,608.0

Price per Share

$186.73

Amount (USD)

$487,002.27

Acquired/Disposed

Disposed

Shares Owned Before

408,637.0

Shares Owned After

406,029.0

Transaction 3

Security

Ordinary Shares

Action

Sell

Date

2026-03-03

Code

S

Net shares

-233.0

Price per Share

$187.84

Amount (USD)

$43,767.75

Acquired/Disposed

Disposed

Shares Owned Before

406,029.0

Shares Owned After

405,796.0

Filing's footnotes

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.500 to $187.4693. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $187.7783 to $188.1678 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.